Boston -Model BOS172738 -ATP-Competitive RET (Rearranged during Transfection) Kinase Inhibitor
BOS172738 is a highly selective, reversible, ATP-competitive RET (Rearranged during Transfection) kinase inhibitor. RET rearrangements and activating mutations are found in multiple solid tumors, but especially with non-small cell lung cancers and medullary thyroid carcinomas.
Most popular related searches
non-small cell lung cancer
thyroid carcinoma
solid tumor
lung cancer
lung cell
thyroid cancer
carcinoma
oncology
cancer cell
- BOS172738 demonstrates potent preclinical activity in RET-driven tumors derived from patient-derived xenografts.
- BOS172738 is highly potent with selectivity to multiple genetically-altered forms of RET kinase, including resistance mutations such as V804M.